The Korea Institute of Science and Technology (KIST, President Oh Sang-rok) held a technology transfer signing ceremony on the 17th at the KIST headquarters in Seongbuk-gu, Seoul, with Huons Biopharma (CEO Kim Young-mok) for the development of a peptide therapeutic for dry age-related macular degeneration.
Under this agreement, the two institutions plan to conduct collaborative research over the next 14 months to accelerate the commercialization of peptide therapy technology for dry age-related macular degeneration targeting the elderly.
President Oh Sang-rok stated, “The collaboration between KIST and Huons Biopharma will serve as a representative example of the BP Plus project, which actively supports the commercialization process of companies that have signed technology transfer contracts.”
Kim Young-mok, CEO of Huons Biopharma, said, “We will work closely with KIST to advance global clinical trials for innovative dry age-related macular degeneration drugs and obtain product approval.”
Huons Biopharma is a subsidiary of the Huons Group engaged in bio-businesses such as botulinum toxin. It was established in 2021 through a spin-off of the bio-business division of Huons Global.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
